Back to top

Image: Bigstock

RPRX vs. ILMN: Which Stock Should Value Investors Buy Now?

Read MoreHide Full Article

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Royalty Pharma (RPRX - Free Report) and Illumina (ILMN - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.

Right now, Royalty Pharma is sporting a Zacks Rank of #2 (Buy), while Illumina has a Zacks Rank of #3 (Hold). This means that RPRX's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.

Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.

RPRX currently has a forward P/E ratio of 12.60, while ILMN has a forward P/E of 37.06. We also note that RPRX has a PEG ratio of 1.34. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. ILMN currently has a PEG ratio of 2.73.

Another notable valuation metric for RPRX is its P/B ratio of 3.97. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, ILMN has a P/B of 9.65.

Based on these metrics and many more, RPRX holds a Value grade of B, while ILMN has a Value grade of D.

RPRX is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that RPRX is likely the superior value option right now.

Published in